MOF-Based unit foR genErATing Hospital-gradE oxygen (BREATHE)

点击翻译按钮获取中文摘要

As COVID-19 infection rates soar across the UK, the number of patients requiring hospital treatment increases proportionally. Unfortunately, there is not yet a targeted effective cure for COVID-19, however, it has been demonstrated that high-flow oxygen improves a patient's chances of survival. Unsurprisingly, the oxygen demand for hospital and home care treatment has significantly increased by 33% in the last 12 months and it is envisaged to continue growing, as the number of COVID cases is expected to further increase in the upcoming months.To meet this increased demand and ensure hospitals and doctors have enough on-demand oxygen capacity to treat the UK population, BREATHE will develop a new generation of energy-efficient oxygen concentrators that enable the production of greater oxygen purity.MOF Technologies is the world-leading company in the manufacturing and commercialisation of metal-organic frameworks (MOFs). MOF Technologies will exploit its product development expertise to develop the first MOF-based oxygen generator. BREATHE will provide improve the on-demand oxygen production in the medical sector by developing an oxygen concentrator with boosted oxygen purity while reducing both unit size and running costs. BREATHE will incorporate a new generation of adsorbents called MOFs to obtain an unsurpassed air separation efficiency and boost O2 purity. BREATHE will increase the number of patients that can have access to medical-grade oxygen, strengthening the UK health care system in these crucial times.